Abstract: A steerable earth boring assembly which includes an annular collar and a drive shaft with a drill bit, where the shaft pivots with respect to the collar. An upper portion of the shaft inserts into an orientation sleeve which resides in the collar. An axial bore is obliquely formed through the sleeve, and in which the upper portion inserts. Rotating the sleeve causes precession of the upper portion, thereby pivoting the drill bit obliquely to the collar. Selective rotation of the sleeve orients the drill bit into a designated orientation for forming a deviated wellbore. Included in the assembly is a flow tube with an end in sealing contact with the drive shaft.

Abstract: The present invention relates to the use of novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), for treating brain diseases and injuries that result in dopaminergic deficiencies and mitochodrial dysfunction, e.g., reduced complex I enzyme activity.

Abstract: A steerable earth boring assembly which includes an annular collar and a drive shaft with a drill bit, where the shaft pivots with respect to the collar. An upstream portion of the shaft inserts into an orientation sleeve which resides in the collar. An axial bore is obliquely formed through the sleeve, and in which the upstream portion inserts. Rotating the sleeve causes precession of the upstream portion, thereby pivoting the drill bit obliquely to the collar. Selective rotation of the sleeve orients the drill bit into a designated orientation for forming a deviated wellbore. Included in the assembly is a flow tube with an end in sealing contact with the drive shall.

Abstract: A steerable earth boring assembly which includes an annular collar and a drive shaft with a drill bit, where the shaft pivots with respect to the collar. An upstream portion of the shaft inserts into an orientation sleeve which resides in the collar. An axial bore is obliquely formed through the sleeve, and in which the upstream portion inserts. Rotating the sleeve causes precession of the upstream portion, thereby pivoting the drill bit obliquely to the collar. Selective rotation of the sleeve orients the drill bit into a designated orientation for forming a deviated wellbore. Included in the assembly is a flow tube with an end in sealing contact with the drive shaft.

Abstract: The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies.

Abstract: The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies.

Abstract: A steerable earth boring assembly which includes an annular collar and a drive shaft with a drill bit, where the shaft pivots with respect to the collar. An upper portion of the shaft inserts into an orientation sleeve which resides in the collar. An axial bore is obliquely formed through the sleeve, and in which the upper portion inserts. Rotating the sleeve causes precession of the upper portion, thereby pivoting the drill bit obliquely to the collar. Selective rotation of the sleeve orients the drill bit into a designated orientation for forming a deviated wellbore. Included in the assembly is a flow tube with an end in sealing contact with the drive shaft.

Abstract: A steerable earth boring assembly which includes an annular collar and a drive shaft with a drill bit, where the shaft pivots with respect to the collar. An upstream portion of the shaft inserts into an orientation sleeve which resides in the collar. An axial bore is obliquely formed through the sleeve, and in which the upstream portion inserts. Rotating the sleeve causes precession of the upstream portion, thereby pivoting the drill bit obliquely to the collar. Selective rotation of the sleeve orients the drill bit into a designated orientation for forming a deviated wellbore. Included in the assembly is a flow tube with an end in sealing contact with the drive shall.

Abstract: A steerable earth boring assembly which includes an annular collar and a drive shaft with a drill bit, where the shaft pivots with respect to the collar. An upstream portion of the shaft inserts into an orientation sleeve which resides in the collar. An axial bore is obliquely formed through the sleeve, and in which the upstream portion inserts. Rotating the sleeve causes precession of the upstream portion, thereby pivoting the drill bit obliquely to the collar. Selective rotation of the sleeve orients the drill bit into a designated orientation for forming a deviated wellbore. Included in the assembly is a flow tube with an end in sealing contact with the drive shaft.

Abstract: The present invention relates to the use of novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), for treating brain diseases and injuries that result in dopaminergic deficiencies and mitochodrial dysfunction, e.g., reduced complex I enzyme activity.

Abstract: This invention provides treatment compositions as well as systems and methods of determining and administering an effective amount of treatment for a neurological disorder. The treatment composition can contain a labeled interfering RNA (iRNA) agent capable of decreasing expression of a target RNA associated with the neurological disorder. The methods of the invention include determining an effective amount of a therapeutic composition by introducing a solution containing a tracer into the brain of a mammal. The tracing solution is monitored until a target volume of distribution at steady state distribution is substantially achieved, and the rate of delivery of the therapeutic composition is determined. The therapeutic composition can then be administered at the rate determined by use of the tracing solution.

Abstract: This invention provides treatment compositions as well as systems and methods of determining and administering an effective amount of treatment for a neurological disorder. The treatment composition can contain a labeled interfering RNA (iRNA) agent capable of decreasing expression of a target RNA associated with the neurological disorder. The methods of the invention include determining an effective amount of a therapeutic composition by introducing a solution containing a tracer into the brain of a mammal. The tracing solution is monitored until a target volume of distribution at steady state distribution is substantially achieved, and the rate of delivery of the therapeutic composition is determined. The therapeutic composition can then be administered at the rate determined by use of the tracing solution.

Abstract: The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies.

Abstract: The present invention relates to the use of novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), for treating brain diseases and injuries that result in dopaminergic deficiencies and mitochodrial dysfunction, e.g., reduced complex I enzyme activity.

Abstract: This invention provides treatment compositions as well as systems and methods of determining and administering an effective amount of treatment for a neurological disorder. The treatment composition can contain a labeled interfering RNA (iRNA) agent capable of decreasing expression of a target RNA associated with the neurological disorder. The methods of the invention include determining an effective amount of a therapeutic composition by introducing a solution containing a tracer into the brain of a mammal. The tracing solution is monitored until a target volume of distribution at steady state distribution is substantially achieved, and the rate of delivery of the therapeutic composition is determined. The therapeutic composition can then be administered at the rate determined by use of the tracing solution.